| Ytd | 15.43% | |
| 1y | 17.49% |
| Open | 11.10 | Prev Close | 11.07 | Low | 11.04 | High | 11.70 | Mkt Cap | 941.86M |
| Vol | 2.98M | Avg Vol | 7.93M | EPS | -3.38 | P/E | N/A | Forward P/E | -4.59 |
| Beta | 1.19 | Short Ratio | 5.61 | Inst. Own | 92.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 6.58 | 200-d Avg | 7.27 | 1yr Est | 18.38 |
REPL News
Replimune Group, Inc. faces a pivotal FDA AdCom for RP1 after two prior rejections, with a final FDA
Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.76) per share which missed the analys
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical st
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D
Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the developme
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-st
FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap
Several stocks, including Optimum Communications Services, surged while Dow fell. Technology, energy
Replimune Group (REPL) shares gain on key RP2 & RP1 oncology data presentations at ASCO. Read th